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Abstract: This feasibility study set out to investigate the use of FDG-PET/DW-MRI in chronic hepatitis C patients to 
examine changes in local liver inflammation after treatment with direct-acting antivirals (DAA). Twelve patients with 
chronic hepatitis C were prospectively enrolled, performing FDG-PET/DW-MRI prior to and after DAA treatment. 
PET/DW-MRI included PET acquisition 60 and 90 min after FDG-injection, DIXON, for attenuation correction, T2- 
and DW-MRI with 10 b-values between 0-700 s/mm2. The following parameters were measured from fusion of 3 
volumes of interest (VOIs) placed in the liver parenchyma: Mean standard uptake value after 60 and 90 minutes 
(SUVmean60 and SUVmean90), total Apparent Diffusion Coefficient (ADC), perfusion fraction (PF), pseudo-diffusion (D*) 
and perfusion-free diffusion (D). We found PET/DW-MRI of chronic hepatitis C patients to be feasible. Patients were 
cooperative, tolerated the scans well and the image quality was acceptable. A total of 10 patients were available for 
final analysis. All patients achieved sustained virologic response and normalized alanine-aminotransferase (ALAT) 
levels after treatment with DAA. Perfusion fraction measured by DW-MRI changed significantly after treatment, from 
mean 0.21 (± 0.04) to 0.26 (± 0.06), P=0.005 and D* from 0.50 (± 0.13) × 10-3 s/mm2 to 0.62 (± 0.15) × 10-3 s/
mm2, P=0.028. All other parameters, including FDG-uptake, was unchanged. These results suggest that liver perfu-
sion is changed shortly after DAA treatment, with no significant change in inflammation. The study concludes that 
PET/DW-MR is feasible in quantifying perfusion and possibly inflammation in chronic hepatitis C patients and may 
be used to follow treatment.
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Introduction
Globally, an estimated 71 million people have 
chronic hepatitis C virus infection (CHC) [1], 
which is associated with hepatic as well as sys-
temic inflammation [2]. Hepatic inflammation 
contributes to the development of fibrosis, cir-
rhosis and hepatocellular carcinoma (HCC) 
[2], leading to approximately 400,000 deaths 
annually [1]. The degree of inflammation in the 
liver has prognostic value in the evaluation of 
progression of liver fibrosis [3], however, hepat-
ic inflammation is difficult to assess non-inva-
sively. Since 2014, direct-acting antiviral agents 
(DAA’s) have been introduced for treatment of 
CHC, resulting in sustained virological response 
(SVR) in the majority of patients (>90%) as well 
as fewer side effects compared to previous 
standard of care [4, 5]. 
Studies have shown though, that not all patients 
show regression in liver fibrosis level after suc-
cessful treatment [6]. Traditionally, evaluation 
of liver fibrosis is done by analysis of liver biop-
sies. There are, however, several problems con-
cerning this invasive procedure: discomfort for 
the patient, an overall complication rate of over 
6%, bleeding risk of 1-2% and even a small mor-
tality [3]. Furthermore, a biopsy only represents 
approximately 1/50,000 of total liver volume, 
sampling errors are frequent and intra- and 
inter-observer variations have been reported 
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[3]. Non-invasive methods for evaluating degree 
of fibrosis, such as transient elastography 
(Fibroscan), exist, but at present there are no 
non-invasive methods in clinical use to score 
liver inflammation. A tool to non-invasively mea-
sure the level of inflammation in the liver to 
guide timing of treatment, as well as monitoring 
local response in the liver after treatment, 
could therefore be a valuable tool in the clinic. 
Recently a number of magnetic resonance 
imaging (MRI) sequences, including MR elas-
tography (MRE) and diffusion weighted MRI 
(DW-MRI), have shown great potential for diag-
nosing and grading fibrosis and local changes 
in the liver [7], but much less is known about 
the usefulness of DW-MRI for evaluating inflam-
mation. DW-MRI is a functional imaging tech-
nique that displays information about water 
mobility, tissue cellularity and the integrity of 
cellular membranes. It also permits the quanti-
tative evaluation of the apparent diffusion coef-
ficient (ADC) from images with different b-val-
ues. ADC values derived from DW-MRI reflects 
the diffusion of water molecules in tissues and 
are therefore influenced both by capillary blood 
flow as well as water diffusion in the extracel-
lular space [8], both of which may be impacted 
by the presence of inflammation. By bi-expo-
nential modeling of multiple b-value DWI, it is 
possible to better account for non-monoexpo-
nential behavior of the diffusion signal intensity 
at different b-values, as well as take into the 
account the influence of perfusion at low b-val-
ues. This allows us to separate the pure molec-
ular diffusion and the perfusion-related diffu-
sion effects on ADC values, into pure diffusion 
(D), pseudo-perfusion (D*) and the perfusion 
fraction (PF). This makes it possible to examine 
the effects of hepatitis C on the liver in greater 
detail. 
Use of Positron Emission Tomography/Com- 
puted Tomography (PET/CT) with the tracer 
18F-Fluordeoxyglucose (18F-FDG) is well descri- 
bed for diagnosing and evaluating inflammato-
ry conditions such as inflammatory bowel dis-
ease, vasculitis and fever of unknown origin, 
and as so, it might be a useful tool to assess 
inflammation over time such as in CHC patients 
[9-11]. FDG-PET has not been systematically 
evaluated in CHC patients, but by comparing 
FDG uptake in individual patients, this method 
may have the potential to be utilized to assess 
inflammation over time in liver disease [12].
PET/DW-MRI is a newly developed medical 
imaging technology combining the non-invasive 
information of tissue at the molecular level of 
PET and the excellent soft tissue differentiation 
as well as the function parameters of MRI [13]. 
The object of this pilot study was to evaluate 
the feasibility of PET/DW-MRI as a clinical tool 
for non-invasive evaluation of liver inflamma-
tion in chronic hepatitis C patients as well as 
changes after DAA treatment. To our knowl-
edge, this is the first study to examine local 
inflammation in the liver with PET/DW-MRI. The 
working hypothesis is that local inflammation 
in the liver of patients with chronic infection 
with hepatitis C virus will decrease after suc-
cessful treatment with DAA’s. 
Methods
Background and patients
This pilot study is a sub-study originating from 
the study “Coagulation and inflammation in 
patients with chronic hepatis C”, which took 
place at Rigshospitalet, Copenhagen University 
Hospital, from September 2014 to July 2015. 
The study was approved by The Committee on 
Biomedical Research Ethics for the Capital 
Region in Denmark (H-1-2014-064) and the 
Danish Data Protection Agency and conducted 
in accordance with the Second Declaration of 
Helsinki. Written informed consent was obtain- 
ed from all participants. 
For this pilot study we planned an inclusion of a 
total of 12 patients. To be eligible, patients had 
to have previously untreated chronic hepatitis C 
with or without fibrosis or cirrhosis, as estimat-
ed by Fibroscan (≥7 kPa for fibrosis and ≥12 
kPa for cirrhosis). Only Child Pugh class A 
patients were eligible. Exclusion criteria were 
Child Pugh class B-C, diabetes, claustrophobia, 
magnetic metal implants and pacemaker. All 
patients had to complete a scan before and 
after treatment with DAA’s to be eligible. All 
patients were recruited from the Department 
of Infectious Diseases and the Department of 
Hepatology at Rigshospitalet, Copenhagen Uni- 
versity Hospital, during the period of September 
2014 to July 2015. 
Blood sampling and treatment
All patients had one blood sample of 30 mL 
taken before and after treatment with DAA. 
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Blood levels of ALAT, CRP, leukocytes and hepa-
titis C viral load were recorded. Treatment dose 
and length of treatment varied between partici-
pants depending on hepatitis C genotype. All 
patients received between 8 and 12 weeks of 
DAA treatment. 
PET/DW-MRI
The pre- and post-treatment scans were per-
formed no more than 14 days prior to, respec-
tively after DAA treatment. FDG-PET/DW-MRI 
(Siemens Biograph mMR) was performed over 
the upper abdomen (1-2 bed positions). All 
patients fasted for a minimum of 4 hours prior 
to FDG-injection. PET was acquired 60 and 90 
min after FDG-injection (2 Mbq/kg, maximum 
250 Mbq). The dose of FDG used is half of what 
is normally used with PET/CT, which is made 
possible by the longer PET-acquisition time (8 
min/bed) compared with standard PET/CT (2-4 
min/bed). PET was reconstructed using 3 itera-
tions, 21 subsets and 4 mm post-filtering). 3 T 
MRI included: 3D VIBE-DIXON for PET attenua-
tion correction  [echo time (TE) 1.23/2.46 ms, 
repetition time (TR) 3.60 ms, voxel size: 4.1 × 
2.6 × 3.1 mm3]; coronal T2 HASTE [TE 92 ms, 
TR 1400 ms, pixel size: 2.1 × 1.5 mm2, slice 
thickness 5.0 mm]; transverse T2 BLADE with 
fat saturation  [TE 95 ms, TR 2500 ms, pixel 
size: 1.5 × 1.5 mm2, slice thickness 5.0 mm]; 
and DW imaging with a prototype single-shot 
spin-echo EPI pulse sequence [TE 64 ms, TR 
2800 ms, pixel size: 3.1 × 3.1 mm2, slice thick-
ness 5.0 mm and 10 b-values: 0, 10, 20, 50, 
100, 180, 300, 420, 550 and 700 s/mm2].
Measurement of ADC and SUV 
An experienced PET-MRI radiologist and a 
nuclear medicine physician placed three vol-
umes of interest (VOI) of each 12-15 cm3 in the 
liver parenchyma, two in the right lobe and one 
in the left, avoiding larger vessels and arte-
facts. After fusion of the 3 VOIs the following 
PET/DW-MRI parameters were extracted: SUV 
mean after 60 minutes (SUVmean60) and SUV 
mean after 90 minutes (SUVmean90), as defined 
as:
SUV r
w
'= ac m
Where r is the radioactivity activity concentra-
tion [kBq/ml] measured by the PET scanner 
within a volume of interest, α’ is the decay-cor-
rected amount of injected radiolabeled FDG 
[kBq], and w is the weight of the patient in 
grams [14]. 
Furthermore, median total ADC (Median AD- 
Ctotal) obtained from single-exponential mod-
eling as well as median Perfusion Fraction (PF), 
D* (pseudo-diffusion) and D (perfusion-free dif-
fusion) obtained from bi-exponential modeling 
of the multiple b-value DWI using the equation 
S/So = PF∙e
-b(D+D*) + (1-PF)∙e-bD
as implemented in a Siemens works-in-prog-
ress research package. 
Table 1. Details on the individual patients included in the analysis
Patient Sex Age BMIi Current smoker
Current alcohol 
consumes
CHC with 
fibrosis
Child-Pugh 
scoreii
HCV 
genotype
HCV RNA load 
(IU/ml)iii
1 M 63 19.2 No No Yes A 3 0.72·106
2 M 66 29.7 Yes Yes Yes A 1 2.50·106
3 M 54 24.6 Yes No No A 1 3.20·106
4 F 45 22.8 No No No A 1 0.80·106
5 M 42 28.4 Yes No Yes A 3 0.79·106
6 F 61 22.9 No Yes Yes A 1 0.39·106
7 M 30 22.6 Yes No No A 2 2.70·106
8 M 40 23.1 No No Yes A 3 3.70·106
9 M 30 24.3 No Yes No A 4 0.85·106
10 M 43 24.1 No No No A 4 1.30·106
iBody Mass Index. iiChild-Pugh Score (A-C) assess the prognosis of chronic liver disease based on total bilirubin, serum albu-
min, prothrombin time, ascites and hepatic encephalopathy, Group A being the best prognostic group. iiiHCV RNA lod prior to 
treatment.
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Statistical analysis
Statistical tests were performed using IBM 
SPSS Statistics 25. Data is expressed as mean 
± standard deviation (SD). Comparison of PET/
DW-MRI parameters in the patient group be- 
fore and after treatment were calculated using 
a Wilcoxon signed-rank test. The conventional 
p-value of 0.05 was used as the cutoff for sta-
tistical significance.
Results 
A total of 12 patients had PET/DW-MRI scans 
performed prior to initiation of DAA treatment. 
One patient was diagnosed with HCC after the 
first scan and was excluded from the study. 
The remaining 11 patients had a second PET/
DW-MRI after 12 weeks of treatment. In 1 
patient MRI failed, leaving 10 patients for the 
final analysis, 10 patients had PET/DW-MRI 
scans performed prior to initiation of DAA treat-
ment and after treatment was completed (2 
women and 8 men with a mean age of 48.3 
years, further characteristics in Table 1).
Effect of DAA treatment on Fibroscan-scores, 
blood liver test and systemic inflammation
Fibrosis level of the liver was assessed by 
Fibroscan. 4 patients had Fibroscan-score over 
12, indicating cirrhosis, 2 had significant fibro-
sis and 4 had no evidence of fibrosis. Average 
HCV load prior to treatment was 1.7 × 106 IU/ml 
(± 1.2 × 106). All patients obtained sustained 
virological response (SVR), defined as unde-
tectable serum HCV RNA 12 weeks after treat-
ment. Average ALAT decreased from 103 (± 92) 
U/l to 22 (± 12) U/l, P=0.005. CRP was within 
the normal range and did not change signifi-
cantly during treatment, nor did leukocytes or 
Fibroscan-score (Table 2) [6]. 
Effect of DAA treatment on local inflammation 
monitored by PET/DW-MRI
An overview of PET/DW-MRI measurements 
before and after treatment can be seen in Table 
3 and Figure 1. Examples of obtained imaging 
from a single patient can be seen in Figure 2. 
The main positive findings were that the perfu-
sion fraction increased from mean 0.21 (± 
0.04) to 0.26 (± 0.06), P=0.005 and D* from 
0.50 (± 0.13) × 10-3 s/mm2 to 0.62 (± 0.15) × 
10-3 s/mm2, P=0.028.  
Prior to and after DAA treatment, SUVmean60 was 
1.93 (± 0.24) and 1.96 (± 0.32), respectively. 
Mean SUVmean90 changed from 1.72 (± 0.29) to 
1.71 (± 0.23). The mean ratio of SUVmean90/
SUVmean60 before treatment was 0.89 (± 0.03), 
after treatment this was 0.88 (± 0.02). None of 
these changes were significant, nor were the 
changes in ADCtotal: 1.02 (± 0.06) to 1.01 (± 
0.09) × 10-3 s/mm2 and D: 0.91 (± 0.04) to 0.87 
(± 0.11) × 10-3 s/mm2. 
Table 2. Blood test results before and after treatment with direct acting antivirals
Mean HCV RNA load (IU/ml) Mean ALAT (U/L) CRP (mg/L) Leukocytes (109/L) Fibroscan (kPa)
Pre-treatment 1.7·106 ±1.2·106 103±92 0.53±0.46 7.60±2.48 11.22±7.78
Post-treatment 0 22±12 0.83±0.71 7.14±2.74 8.08±6.07
p-value 0.005 0.005 0.066 0.333 0.249
Fibroscan after treatment was only completed in 6 patients. Mean HCV RNA load and mean ALAT decreased significantly after 
treatment.
Table 3. Summary of PET/DW-MR imaging data before and after treatment with direct acting  
antivirals
Median ADCtotal  
(× 10-3 mm2/s) *Perfusion fraction
Diffusion, D  
(× 10-3 mm2/s)
*Pseudo-diffusion, D*  
(× 10-3 mm2/s)
Pre-treatment 1.02±0.06, 1.00, 0.98-1.06 0.21±0.04, 0.21, 0.18-0.24 0.91±0.04, 0.90, 0.89-0.94 0.50±0.13, 0.50, 0.41-0.60
Post- treatment 1.01±0.09, 1.04, 0.95-1.08 0.26±0.06, 0.25, 0.22-0.30 0.87±0.11, 0.87, 0.80-0.94 0.62±0.15, 0.60, 0.51-0.73
SUVmean60 SUVmean90 SUVmean90/SUVmean60
Pre-treatment 1.93±0.24, 2.00, 1.76-2.10 1.72±0.29, 1.85, 1.51-1.93 0.89±0.03, 0.90, 0.65-1.05
Post-treatment 1.96±0.32, 1.85, 1.73-2.19 1.71±0.23, 1.75, 1.54-1.88 0.88±0.02, 0.88, 0.84-0.91
Group data presented as mean ± standard deviation, median, 95 % confidence interval. *Perfusion fraction and D* changes significantly.
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There was no significant correlation between 
Fibroscan-score and SUV or ADC values. Like- 
wise, no correlation was found between Fibro- 
scan-score and the changes in ADC or SUV 
before/after treatment (data not shown). Figure 
3 suggests a correlation between the differ-
ence in SUV ratio ( SUV
SUV
mean60
mean90 ) before and after 
treatment and perfusion fraction, with increas-
ing perfusion fraction correlated with larger dif-
ference in SUV-ratio before and after treat- 
ment.
Discussion
We found PET/DW-MRI of chronic hepatitis C 
patients to be feasible. Patients were coopera-
tive and tolerated the scans well. The image 
quality was acceptable with no artefacts in 22 
out of 23 images (The second scan in 1 patient 
failed and another patient was excluded after 
the first scan showed hepatocellular carcino- 
ma).
Our pilot study found that perfusion fraction 
and D* measured by DW-MRI changed signifi-
cantly after treatment with DAA’s, both of whi- 
ch are dependent on perfusion. To determine 
whether this increase in perfusion of the liver is 
a direct result from treatment or an epiphe-
nomenon requires further studies, as system-
atic Fibroscan of all patients after treatment 
were not completed. The incomplete data does 
however suggest a decrease in Fibroscan- 
score.
Despite all patients obtaining sustained viro-
logical response (SVR) with undetectable viral 
replication and normalized ALAT, our pilot study 
found that the DAA treatment did not signifi-
cantly change the liver mean SUV or median 
ADC. With normalization of liver blood test 
results, we expected, as per our working 
hypothesis, that the reduction in liver inflam-
mation post-treatment would be visible as 
changes in both SUV-uptake and total ADC. 
Figure 1. Selected PET/DW-MRI parameters before and after treatment. Only perfusion fraction is significantly im-
proved after treatment, while the rest of the displayed parameters did not significantly change.
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SUV is a quantitative measure of cellular glu-
cose metabolism and has been shown to cor-
relate with inflammation elsewhere in the body, 
such as inflammatory bowel disease and some 
types of vasculitis [10] as well as local lesions 
in the liver, for instance liver abscesses [11]. 
We therefore anticipated a decrease in mean 
SUV after the patients obtained SVR with nor-
malized ALAT, but our findings show that its 
usefulness in diffuse liver diseases may be lim-
ited or at least require further examination. A 
possible explanation could be that mean liver 
The mechanism of diffusion restriction mea-
sured with DW-MRI in CHC patients is not 
understood in detail yet, but is possibly in part 
caused by the extracellular matrix deposition of 
proton-poor macromolecules such as collagen, 
fibrous scar formation as well as decreased 
blood flow [17]. Studies have found that ADC 
values significantly differ between healthy sub-
jects and CHC patients [18-20], but studies dis-
agree on whether the presence of inflammation 
(assessed by liver biopsy) alter the diffusion 
properties of the tissue and therefore the ADC 
Figure 2. A-F: Examples of images obtained in a single patient prior to treatment. Main tissues marked as follows: 
*Right liver lobe, **Gall bladder, #Stomach, ¤Spleen and §Kidney. A: Transaxial T2 BLADE. B: Transaxial FDG PET. 
C: Transaxial combined FDG-PET/MRI (T2 BLADE). D: Coronal T2 Haste. E: Transaxial ADC map with volume of inter-
est (VOI) placed in right liver lobe. F: Transaxial mapped Perfusion Fraction (PF).
Figure 3. Post- and pre-treatment difference in mean SUV ratio ( SUV
SUV
mean60
mean90 ) & 
difference in perfusion fraction. A correlation between SUV ratio and perfu-
sion fraction, with increasing perfusion fraction correlated with larger differ-
ence in FDG-retention ratio before and after treatment. 
SUV uptake in chronic hepati-
tis C patients does not differ 
from the liver SUV of healthy 
individuals. Paquet et al. 
found the mean SUV of 70 
cancer-free patients to be 
2.02 (± 0.39), which was sta-
ble over time [15], and Meyer 
et al. [16] found the mean liver 
SUV to be 2.16 from a total of 
389 cases [16]. The SUVmean60 
of this study was 1.93 (± 
0.24). Although it is not possi-
ble to directly compare these 
results because of differenc-
es in e.g. study model, equip-
ment and patients, it suggests 
that the liver SUV of healthy 
individuals and CHC patients 
might be comparable.  
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values. Some studies found no significant cor-
relation between inflammation score and ADC 
values [18, 21-24]. Other studies did find sig- 
nificant correlation between parameters, but 
it disappeared after using multiple regression 
[25], after adjusting for fibrosis [26] or when 
considering fibrosis and inflammation together 
[8]. The last group of studies, however, report-
ed a significant correlation between ADC values 
and inflammation [20, 27-30], suggesting that 
the ADC values might reflect the intensity of 
inflammation, but different patient populations, 
varying methods of histological methods for 
scoring inflammation and technical parameters 
(e.g. manufacturer, field strength, b values) dif-
fer between studies and makes direct compari-
son difficult. Further effort should be made to 
standardize DW-MRI-protocols of the liver to 
make research using this image modality more 
easily comparable. 
In this pilot study of 10 patients that all achieved 
SVR, we found no significant difference bet- 
ween ADC values before and after treatment. 
Due to low sample size, the power in our study 
was limited. If presence of inflammation has a 
direct effect on ADC values, it has not been 
substantial enough in our patient population to 
show a difference after reaching sustained viro-
logical response, where we would expect the 
inflammation to have subsided. In the same 
manner, Gúrcan N. et al. [31], found no differ-
ence in ADC values at follow-up 12 weeks after 
a 12-week treatment with Telaprevir-based 
treatment for hepatitis C. Several studies have 
highlighted the relationship between ADC and 
varying degrees of fibrosis and cirrhosis, with 
higher stages resulting in lower ADC values [17, 
27, 28]. If the diffusion properties of the tissue 
reflected in ADC values are less dependent on 
inflammation, but more so on fibrosis, it might 
explain why there is no change this early after 
the treatment with DAA. Even though there is 
emerging evidence that fibrosis and cirrhosis 
might be at least partly reversible [32], it might 
be too early to see these changes reflected in 
the ADC value from the post-treatment scan 
done within 14 days of the last treatment. The 
correlation between ADC values and fibrosis 
found in several studies is however being chal-
lenged. A rat study from 2007 found that the 
correlation between ADC values and fibrosis 
may be the result of a decrease in perfusion, 
suggesting that changes in perfusion is the pri-
mary reason behind effects on ADC values 
[33]. Our study found a significant increase in 
perfusion fraction as well as in D*, suggesting 
that treatment of the disease helps increase 
perfusion in the liver. Considering that an 
increase in perfusion in the liver after treat-
ment might influence the FDG-uptake of the 
liver cells, changes in the ratio of SUVmean90/
SUVmean60 were plotted against changes in PF. 
This plot proposes a connection between the 
two parameters as seen on Figure 3, suggest-
ing that improvements in perfusion fraction is 
correlated with a bigger difference in FDG-
retention from 60 to 90 minutes. This supports 
the notion that FDG-uptake is not only depen-
dent on the presence of inflammatory cells, but 
also on perfusion, though not significant in our 
small study (R² = 0.3231). It is thus possible 
that the decrease in FDG-uptake we expected 
is hidden by the increased perfusion after 
treatment. 
Whether or not PET/DW-MRI could be a useful 
tool to separate changes in FDG-uptake caused 
by changes in perfusion from changes in the 
number of inflammatory or malignant cells 
should be explored in future studies, as well as 
whether or not the changes in perfusion can be 
useful in predicting treatment response, for 
example identifying none-responders or those 
patients who do not experience regression in 
their liver fibrosis.
Our pilot study had several limitations. Only 
data from 10 patients were included in the final 
analysis and the patient group was diverse with 
all patients having varying stages of liver dis-
ease as determined by Fibroscan. The absence 
of histopathologic correlation during and after 
treatment to assess the parenchymal changes 
in the liver is one of the main limitations of this 
pilot study. Without this reference, it is difficult 
to assess the change in inflammatory activity 
before and after treatment, even though SVR 
and normalized ALAT suggests such a change. 
Conclusion
This pilot study is, to our knowledge, the first to 
examine chronic hepatitis C patients with PET/
DW-MRI and it was found feasible. All partici-
pants received SVR and ALAT decreased after 
treatment with DAA. 
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Perfusion fraction and D* measured by DW-MRI 
changed significantly after treatment. It has 
been shown that liver total ADC values differ 
significantly between CHC patients and healthy 
individuals, but we did not see an effect on 
total ADC after treatment, possibly because the 
scan was done early after treatment. All other 
PET/DW-MRI parameters, including FDG-up- 
take were unchanged. This suggests that treat-
ment with DAA may increase blood perfusion in 
the liver, but that the degree of inflammation in 
the liver of CHC patients may not differ enough 
from healthy individuals to be seen with FDG-
PET. This should be explored further with a 
larger population and liver biopsy for histologi-
cal comparison. The suggested correlation bet- 
ween SUV ratio and PF confirms that FDG-up- 
take is dependent on perfusion as well as in- 
flammatory or malignant cell activity. The role 
of PET/DW-MRI in separating changes in FDG-
uptake caused by changes in perfusion from 
changes in cellular activity is promising and 
should be explored in future studies, which may 
also help define a possible role for PET/DW-MRI 
in monitoring the liver of chronic hepatitis C 
patients after treatment with DAA’s.
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